SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases ...

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

Fintel reports that on November 20, 2024, Evercore ISI Group initiated coverage of SpringWorks Therapeutics (NasdaqGS:SWTX) ...

Massachusetts Financial Services Co. MA lifted its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 20.2% during the 3rd quarter, Holdings Channel reports. The firm ...

Mutual of America Capital Management LLC trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free ...

J.P. Morgan said its top biotech picks for 2025 were Vertex, Travere, SpringWorks, PTC Therapeutics, Wave Life Sciences, ...

Springworks Therapeutics (SWTX – Research Report) received a Buy rating and a $60.00 price target from Evercore ISI analyst Cory Kasimov today.

In a report released on November 19, Anupam Rama from J.P. Morgan maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report), ...

In this article, we are going to take a look at where SpringWorks Therapeutics Inc. (NASDAQ:SWTX) stands against the other NASDAQ stocks. Potomac Wealth Advisors president Mark Avallone joined ...

So if the company, for example, their drug candidate is approved, much like, let's say, SpringWorks Therapeutics (SWTX), ...